This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dolan, M. E. Articles by Pegg, A. E. Search for Related Content PubMed PubMed Citation Articles by Dolan, M. E. Articles by Pegg, A. E.

Effect of O⁶-Alkylguanine Pretreatment on the Sensitivity of Human Colon Tumor Cells to the Cytotoxic Effects of Chloroethylating Agents¹

Department of Physiology and Cancer Research Center, The Milton S. Hershey Medical Center, The Pennsylvania State University, College of Medicine, Hershey, Pennsylvania 17033

Two human colon carcinoma cell lines which differ greatly in their content of O⁶-alkylguanine-DNA alkyltransferase were analyzed for their response to 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 2-chloroethyl(methylsulfonyl)methanesulfonate (ClEtSoSo) before and after treatment with O⁶-alkylguanines. HT29 cells contained about 17 times more alkyltransferase activity than BE cells. The alkyltransferase activity of HT29 cells was reduced by 60–80% by treatment for 24 h with 0.05–0.4 mM O⁶-methylguanine or O⁶-n-butylguanine. Such pretreatment prior to exposure to CCNU or ClEtSoSo increased the sensitivity of HT29 cells to these drugs. The exposure to O⁶-alkylguanines gave a greater enhancement of the toxic effects of ClEtSoSo than of CCNU. There was no significant increase in the toxicity of these agents towards the BE cells which contained much lower levels of the alkyltransferase. When added alone neither O⁶-methylguanine nor O⁶-n-butylguanine showed any toxicity towards HT29 or BE cells at the doses used. These results provide strong evidence that the formation of adducts at the O⁶-position of guanine by these agents contributes significantly to their lethality and that this reaction is more critical for ClEtSoSo than CCNU. The enhancement of the activity of chloroethylating agents by pretreatment with nontoxic doses of O⁶-alkylguanines may be clinically useful in terms of increasing their therapeutic efficacy towards cells containing high levels of alkyltransferase.

¹ This research was supported by grant CA-18137 from the National Cancer Institute.

Received 3/ 5/86. Revised 5/ 1/86. Accepted 6/ 2/86.

This article has been cited by other articles:

				T. Ueno, S. H. Ko, E. Grubbs, Y. Yoshimoto, C. Augustine, Z. Abdel-Wahab, T.-Y. Cheng, O. I. Abdel-Wahab, S. K. Pruitt, H. S. Friedman, et al. Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. Mol. Cancer Ther., March 1, 2006; 5(3): 732 - 738. [Abstract] [Full Text] [PDF]

				H. S. Friedman, S. Keir, A. E. Pegg, P. J. Houghton, O. M. Colvin, R. C. Moschel, D. D. Bigner, and M. E. Dolan O6-Benzylguanine-mediated Enhancement of Chemotherapy Mol. Cancer Ther., September 1, 2002; 1(11): 943 - 948. [Abstract] [Full Text] [PDF]

				J. A. Quinn, J. Pluda, M. E. Dolan, S. Delaney, R. Kaplan, J. N. Rich, A. H. Friedman, D. A. Reardon, J. H. Sampson, O. M. Colvin, et al. Phase II Trial of Carmustine Plus O6-Benzylguanine for Patients With Nitrosourea-Resistant Recurrent or Progressive Malignant Glioma J. Clin. Oncol., May 1, 2002; 20(9): 2277 - 2283. [Abstract] [Full Text] [PDF]

				S. L. Gerson Clinical Relevance of MGMT in the Treatment of Cancer J. Clin. Oncol., May 1, 2002; 20(9): 2388 - 2399. [Abstract] [Full Text] [PDF]

				E. L. Kreklau, M. Limp-Foster, N. Liu, Y. Xu, M. R. Kelley, and L. C. Erickson A novel fluorometric oligonucleotide assay to measure O 6-methylguanine DNA methyltransferase, methylpurine DNA glycosylase, 8-oxoguanine DNA glycosylase and abasic endonuclease activities: DNA repair status in human breast carcinoma cells overexpressing methylpurine DNA glycosylase Nucleic Acids Res., June 15, 2001; 29(12): 2558 - 2566. [Abstract] [Full Text] [PDF]

				H. S. Friedman, J. Pluda, J. A. Quinn, R. B. Ewesuedo, L. Long, A. H. Friedman, I. Cokgor, O. M. Colvin, M. M. Haglund, D. M. Ashley, et al. Phase I Trial of Carmustine Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma J. Clin. Oncol., October 20, 2000; 18(20): 3522 - 3528. [Abstract] [Full Text] [PDF]

				E. L. Kreklau, C. Kurpad, D. A. Williams, and L. C. Erickson Prolonged Inhibition of O6-Methylguanine DNA Methyltransferase in Human Tumor Cells by O6-Benzylguanine In Vitro and In Vivo J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1269 - 1275. [Abstract] [Full Text]

				C. L. Nutt, N. A. Loktionova, A. E. Pegg, A. F. Chambers, and J.g. Cairncross O6-Methylguanine-DNA methyltransferase activity, p53 gene status and BCNU resistance in mouse astrocytes Carcinogenesis, December 1, 1999; 20(12): 2361 - 2365. [Abstract] [Full Text] [PDF]

				M. Berardini, P. L. Foster, and E. L. Loechler DNA Polymerase II (polB) Is Involved in a New DNA Repair Pathway for DNA Interstrand Cross-Links in Escherichia coli J. Bacteriol., May 1, 1999; 181(9): 2878 - 2882. [Abstract] [Full Text]